0.68  0.024 (3.66%)		07-26 16:00
Open: 0.6656 High: 0.695 Volume: 108,293		Pre. Close: 0.656 Low: 0.66 Market Cap: 20(M)

Short term
Mid term
Targets	6-month :	0.87	1-year :	1
Resists	First :	0.74	Second :	0.85
Pivot price	0.66
Supports	First :	0.56	Second :	0.47
MAs	MA(5) :	0.65	MA(20) :	0.69
	MA(100) :	2.02	MA(250) :	1.5
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	23.7	D(3) :	16.9
RSI	RSI(14): 47.3
52-week	High :	9.37	Low :	0.56

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VINC ] has closed below upper band by 36.2%. Bollinger Bands are 96.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 61 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.7 - 0.7	0.7 - 0.7
Low:	0.65 - 0.66	0.66 - 0.66
Close:	0.67 - 0.68	0.68 - 0.68

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Tue, 14 May 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network

Tue, 14 May 2024
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Fri, 26 Apr 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - GlobeNewswire

Fri, 26 Apr 2024
Why Vincerx Pharma (VINC) Stock Is Falling - Benzinga

Tue, 09 Apr 2024
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study - Yahoo Finance

Tue, 09 Apr 2024
Vincerx stock drops on data for cancer drug (NASDAQ:VINC) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	30 (M)
Shares Float	23 (M)
Held by Insiders	18 (%)
Held by Institutions	37 (%)
Shares Short	590 (K)
Shares Short P.Month	612 (K)

EPS	-1.78
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.03
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-74.1 %
Return on Equity (ttm)	-224.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.17
Qtrly Earnings Growth	0 %
Operating Cash Flow	-35 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-0.39
PEG Ratio	0
Price to Book value	-22.67
Price to Sales	0
Price to Cash Flow	-0.58

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.